A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

NCT02920424 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study.

Conditions

Interventions

Sponsor

Janssen Research & Development, LLC